Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Closed 12-18 16:00:00 EST

17.07

+0.70

+4.28%

盘后17.45

+0.38+2.23%

19:47 EST

High17.88	Low16.50	Vol801.58K
Open16.60	D1 Closing16.37	Amplitude8.43%
Mkt Cap534.12M	Tradable Cap267.87M	Total Shares31.29M
T/O13.89M	T/O Rate5.11%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":17.07,"timestamp":1766091600000,"preClose":16.37,"halted":0,"volume":801575,"hourTrading":{"tag":"盘后","latestPrice":17.45,"preClose":17.07,"latestTime":"19:47 EST","volume":51531,"amount":883235.6,"timestamp":1766105225650},"delay":0,"floatShares":15692500,"shares":31289969,"eps":-1.898372,"marketStatus":"Closed","change":0.7,"latestTime":"12-18 16:00:00 EST","open":16.6,"high":17.88,"low":16.5,"amount":13890421.03325,"amplitude":0.084301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.898372,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":16.37,"preHourTrading":{"tag":"盘前","latestPrice":16.82,"preClose":16.37,"latestTime":"09:25 EST","volume":3020,"amount":50651.02928,"timestamp":1766067917561},"postHourTrading":{"tag":"盘后","latestPrice":17.45,"preClose":17.07,"latestTime":"19:47 EST","volume":51531,"amount":883235.6,"timestamp":1766105225650},"volumeRatio":0.309325,"impliedVol":1.0118,"impliedVolPercentile":0.7955},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2592113135","title":"PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592113135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592113135?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:17","pubTimestamp":1766107027,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7067","BK4139","BK4539","BK4007","PYC.AU"],"gpt_icon":0},{"id":"2592909268","title":"Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909268","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909268?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:30","pubTimestamp":1766064600,"startTime":"0","endTime":"0","summary":"DOYLESTOWN, Pa., Dec.  18, 2025  (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4007","BK4139","LENZ","BK4097","LU2065732104.USD","BK4539"],"gpt_icon":0},{"id":"2592108909","title":"Akari Therapeutics Releases Virtual Investor “What This Means” Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592108909","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592108909?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:30","pubTimestamp":1766064600,"startTime":"0","endTime":"0","summary":"Watch the “What This Means” video here TAMPA, Fla. and LONDON, Dec.  18, 2025  (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207706/0/en/Akari-Therapeutics-Releases-Virtual-Investor-What-This-Means-Segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2592490980","title":"Piper Sandler Initiates Coverage on Oruka Therapeutics With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490980","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592490980?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:25","pubTimestamp":1766064358,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has an average rating of Buy and mean price target of $49.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2592909176","title":"Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909176","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909176?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063100,"startTime":"0","endTime":"0","summary":"STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207689/33816/en/Sangamo-Therapeutics-Initiates-Rolling-Submission-of-BLA-to-U-S-FDA-for-ST-920-in-Fabry-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2592909294","title":"CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909294","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909294?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062800,"startTime":"0","endTime":"0","summary":"DefenCath demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec.  18, 2025  (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207654/0/en/CorMedix-Therapeutics-Announces-Positive-Data-From-Ongoing-Real-World-Evidence-Study-of-DefenCath.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USRC","BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2592092509","title":"Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592092509","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592092509?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062800,"startTime":"0","endTime":"0","summary":"OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207665/0/en/Ovid-Therapeutics-Reports-Phase-1-Results-for-the-First-Ever-Direct-Activator-of-Potassium-Chloride-Cotransporter-2-KCC2-OV350-Intravenous-IV.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","GABA","LENZ","BK4211","BK4139"],"gpt_icon":0},{"id":"2592997042","title":"Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997042?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:36","pubTimestamp":1766057761,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has an average rating of buy and mean price target of $34.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","LENZ"],"gpt_icon":0},{"id":"2592949765","title":"Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592949765","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592949765?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:59","pubTimestamp":1766012340,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., Dec.  17, 2025  (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207378/0/en/Kalaris-Therapeutics-Announces-Oversubscribed-50-0-Million-Private-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","KLRS","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2592948085","title":"Vistagen Therapeutics Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2592948085","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592948085?lang=en_us&edition=fundamental","pubTime":"2025-12-18 04:46","pubTimestamp":1766004360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VTGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 15:46 ET (20:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","VTGN","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2592127929","title":"Maxim Downgrades Vistagen Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592127929","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592127929?lang=en_us&edition=fundamental","pubTime":"2025-12-18 01:43","pubTimestamp":1765993412,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics (VTGN) has an average rating of overweight and mean price target of $11.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2592916232","title":"Summit Therapeutics Raised to Equal-Weight From Underweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592916232?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:55","pubTimestamp":1765983300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 09:55 ET (14:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","LENZ"],"gpt_icon":0},{"id":"2592261913","title":"Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2592261913","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592261913?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:05","pubTimestamp":1765980300,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints.The stock traded 73% lower ahead of the morning bell at $1.18.The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study.The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements.The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life.Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration.\"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsisten","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","BK4539","VTGN"],"gpt_icon":0},{"id":"2592599024","title":"Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2592599024","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592599024?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:10","pubTimestamp":1765977017,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc (SMMT) has an average rating of Buy and mean price target of $34, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2592990193","title":"Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990193","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990193?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee , advancing the company's first bi-valent siRNA into clinical development. The Phase 1 trial is expected to begin dosing in Q1 2026.RN5681 is a GalNAc-conjugated, dual-targeting siRNA designed to simultaneously silence both PCSK9 and LPA, two genetically validated and complementary drivers of atherosclerotic cardiovascular disease. By unifying LDL-C lowering and Lp reduction within a single molecule, RN5681 aims to deliver deep, durable lipid improvement and address persistent residual risk not resolved by current therapies.\"As a clinician who has helped bring lipid-lowering therapies to patients, I see exceptional promise in a bi-valent siRNA approach,\" said Alex DePaoli, MD, CMO. \"RN5681 has the potential to expand the treatment paradigm by tackling two of the ","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2845384/Rona_Therapeutics_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845384/Rona_Therapeutics_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rona-therapeutics-unveils-the-global-first-bi-valent-pcsk9-lpa-sirna-into-clinical-development-for-cardiovascular-risk-reduction-302644452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CSII","LPA","BK4082","BK4139","BK4539","BK4233","LENZ"],"gpt_icon":0},{"id":"2592997484","title":"Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997484","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997484?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:40","pubTimestamp":1765975237,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc (SYRE) has an average rating of buy and mean price target of $53.58, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2592979199","title":"Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592979199?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Dec.  17, 2025  (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206904/0/en/Acrivon-Therapeutics-to-Announce-Clinical-Update-on-its-Ongoing-Phase-2b-Studies-and-Planned-Confirmatory-Phase-3-Trial-for-ACR-368-Initial-Clinical-Data-on-ACR-2316-and-Other-AP3-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","ACR","LENZ","BK4139","BK4110"],"gpt_icon":0},{"id":"2592696071","title":"Canaccord Genuity Starts Alterity Therapeutics at Speculative Buy with AU$1.60 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592696071","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592696071?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:41","pubTimestamp":1765960862,"startTime":"0","endTime":"0","summary":"Canaccord Genuity Starts Alterity Therapeutics at Speculative Buy with AU$1.60 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2592967216","title":"Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967216","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592967216?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:10","pubTimestamp":1765959000,"startTime":"0","endTime":"0","summary":"LEROCHOL is a novel, third-generation PCSK9 inhibitor designed to help patients achieve and maintain their LDL-C targets. It is self-administered as a once-monthly, single small-volume subcutaneous injection with extended room-temperature stability , giving patients the freedom to administer it where and when they choose. These features make LEROCHOL a unique alternative to other PCSK9 inhibitors.The FDA approval of LEROCHOL was based on data from the comprehensive global Phase 3 LIBerate Clinical Trial Program, which enrolled a diverse population of over 2,900 patients with cardiovascular disease , or without but at very high or high risk for CVD, including HeFH.In clinical trials, LEROCHOL demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of CVD and 59% in those with HeFH who have more severe LDL-C elevations. LEROCHOL was generally well tolerated across the LIBerate Clinical Trial Program. Lerodalcibep is expected to expand treatment opti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-that-licensing-partner-lib-therapeutics-has-received-us-fda-approval-of-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol-302644459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","BK7129","BLA.AU","BK4007","LENZ","BK4139","EMA","EMA.AU","BK4539","BK4081","LDL"],"gpt_icon":0},{"id":"2592969900","title":"D. Western Therapeutics-Linked Glaucoma Eye Drop Launches in Malaysia","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592969900?lang=en_us&edition=fundamental","pubTime":"2025-12-17 14:30","pubTimestamp":1765953002,"startTime":"0","endTime":"0","summary":"D. Western Therapeutics Institute  said sales of a glaucoma and ocular hypertension treatment developed from its research have begun in Malaysia through partner Kowa , according to a Wednesday filing on the Tokyo Stock Exchange.The product, GLA-ALPHA Combination Ophthalmic Solution, is a fixed-dose eye drop. It is the first combination treatment of its kind and can be used alongside other therapies.Kowa has sold the drug in Japan since late 2022, with overseas expansion underway. Sales started in Thailand in July, and approval has also been secured in Singapore.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","BK4168","BK4139","WRN","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":-0.3462},{"period":"1month","weight":-0.363},{"period":"3month","weight":-0.6073},{"period":"6month","weight":-0.4532},{"period":"1year","weight":-0.4949},{"period":"ytd","weight":-0.433}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.169631},{"month":2,"riseRate":0.5,"avgChangeRate":0.077415},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.035986}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction